Specialists diagnose amyotrophic lateral sclerosis (ALS) twice as fast as general neurologists, research led by the ALS Association in collaboration with leading ALS clinicians shows. The average time for ALS or neuromuscular specialists to diagnose ALS…
Specialists twice as fast as general neurologists at diagnosing ALS
It’s been a rough season lately in terms of finding care for my husband, Todd. One of his long-term nighttime caregivers gave notice last summer about moving on. Not only did she work two nights per week, but she was also flexible enough to pick up additional shifts, even on…
People with amyotrophic lateral sclerosis (ALS) are more likely than those without the neurodegenerative disease to have grown up in rural areas, have younger parents, and have lower levels of education, a new study found. These results suggest that events and conditions in early life may be potential environmental…
Something was missing from the packet of patient information my doctor gave me on the day she told me I had ALS. But I didn’t discover that missing item until 12 months later. Why? During those months, even though I was adapting as best I could — such as…
The U.S. Food and Drug Administration (FDA) signaled that it may be willing to consider granting accelerated approval to CNM-Au8 to treat amyotrophic lateral sclerosis (ALS), based on data from clinical trials and ongoing expanded access programs. The therapy’s developer, Clene, said it will put together an…
MN-166 (ibudilast), an investigational oral treatment for amyotrophic lateral sclerosis (ALS), appears to slow disease progression over up to one year of use, according to an analysis of data in an ongoing Phase 2b/3 clinical trial. The interim analysis, required under the study’s design, looked into how well…
Quralis has dosed the first patient in a Phase 1 clinical trial testing QRL-101 — its treatment candidate for reducing nerve cell overactivation in amyotrophic lateral sclerosis (ALS) and thus potentially slowing disease progression — in adults with ALS. The proof-of-mechanism QRL-101-04 trial (NCT06714396) is still enrolling…
MaaT033, an experimental oral therapy for improving the gut microbiome — the collection of microbes, including bacteria, in the human gut — was deemed safe and well tolerated in people with amyotrophic lateral sclerosis (ALS) after two months of dosing. That’s according to a new analysis from an independent…
Life at home with ALS becomes like “Groundhog Day,” the 1993 film starring Bill Murray, in which the main character, Phil, is stuck in a time loop and is forced to live the same day over and over. But there’s something in us that craves novelty, and Phil goes…
The technology company Unlearn is teaming up with APST Research to create “digital twins” to support clinical trials for amyotrophic lateral sclerosis (ALS). Clinical data from more than 8,000 ALS patients in APST’s database will be fed into Unlearn’s Digital Twin Generator (DTG), an artificial intelligence…
Recent Posts
- Feeding wildlife reminded me what’s important in life after ALS
- Inflammatory bacterial sugar in gut may drive ALS risk: Study
- A dream takes me back to a time before life with ALS
- ALS ONE joining ALS Network to strengthen research, services
- Rollator revamp needed because design matters for living well with ALS